Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Study questions efficacy of weight loss drugs
The scientists based at Oregon Health & Science University have highlighted the complexities of the body’s weight regulation system using rodent models of obesity showing the multifarious factors
The scientists based at Oregon Health & Science University have highlighted the complexities of the body’s weight regulation system using rodent models of obesity showing the multifarious factors
The product, which has approval for 2mg and 4mg dosages, will be marketed under the retailers own brand labels. Retail sales for Commit lozenges were approximately $100 million
Macugen, co-developed by Pfizer and OSI Pharmaceuticals, is the first treatment to target the underlying disease process and has been proven to help preserve visual acuity in patients
The phase III study randomly assigned 771 patients to receive standard chemotherapy using dacarbazine with or without Genasense (oblimersen). Prior to randomization, patients were stratified on the basis
The phase I trial of CB7630 will be conducted at the University of California San Francisco Comprehensive Cancer Center with Dr Charles Ryan, as the principal investigator of
Hylenex is a liquid injectable formulation that includes the active pharmaceutical ingredient, recombinant human hyaluronidase (rHuPH20). Morphine is a widely used drug for pain management and is currently
The new formulation allows a convenient way for patients to take a 4mg dose of the drug using the Imitrex STATdose system. Previously patients did not have a
The drug also received orphan-drug designation last year for the treatment of patients with follicular, medullary, anaplastic, and locally advanced and metastatic papillary thyroid cancer. There is currently
The treatment will be indicated for adult patients with newly diagnosed glioblastoma multiforme (GBM), a form of malignant brain cancer. Temodal (temozolomide) is currently marketed in Canada for
According to the company, the trial of the drug in wet age-related macular degeneration (AMD) is the first ever phase II efficacy trial for a small interfering RNA